Pendulum on Fullscript

Pendulum: Revolutionizing gut health through science and innovation

Clinically-studied, proprietary strains designed to transform health through the gut microbiome.*

Loading navigation...

Reimagine the health of your patients by targeting the gut microbiome

Using cutting-edge technology and microbiome science, Pendulum was the first company in the US to market live Akkermansia muciniphila. Akkermansia supports the synthesis of health-promoting postbioitics and strengthens gut barrier integrity.*

Pendulum’s Akkermansia-containing formulations have been clinically studied and published in the British Medical Journal. Improving gut barrier function and maintaining healthy blood sugar levels with Pendulum’s strains is a foundational way to help your patients find optimal health by harnessing the power of the gut microbiome.*

Featured product

Join the 15,000+ practitioners recommending Pendulum Akkermansia

Akkermansia 100 Pro
Maintain keystone strain levels Regular strength live Akkermansia muciniphila helps maintain gut health, supports the gut lining, and manages gut permeability.*

Akkermansia 500 Pro
Replenish keystone strain levels Maximum strength live Akkermansia muciniphila—ideal for patients with advanced indications of intestinal barrier permeability, replenishing this critical strain for optimal gut health.^*

Fullscript and Pendulum provider survey with Akkermansia 500 Pro

98%

Will continue to recommend Akkermansia 500 Pro**

94%

Would recommend Akkermansia 500 Pro to other health care providers**

Study

How providers are using a GLP-1 probiotic in clinical practice

In survey conducted in 2024 of healthcare providers who use a GLP-1 Probiotic

  • 97% of healthcare providers recommend as a way to manage food cravings+
  • 78% Recommend as a strategy to help patients transition off of GLP-1 medications, specifically to help manage food cravings associated with this transition+
  • 64% Recommend as a first line approach before prescribing a GLP-1 medication+
  • 53% Recommend in combination with GLP-1 medications+

Glucose control clinical efficacy

Pendulum conducted a double-blind, placebo-controlled nutrition study that demonstrated:

  • Pendulum Glucose Control’s safety for its intended use
  • Glucose control has a significant statistical and clinical impact on A1c and post-meal blood sugar spikes3
  • -0.6 A1c reduction
  • -32.5% post prandial glucose spike reduction

Fullscript accounts are $0/month — for everyone

Get your practice and patients up and running quickly at no cost.

References

^ Based on preclinical studies
1, 2 Based on a multicenter, double-blind, randomized placebo-controlled trial
3 Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation, Fanny Perraudeau et al, https://drc.bmj.com/content/8/1/e001319
**Survey results from 82 providers who recommended or purchased Akkermansia 500 million AFU between January-July 2024 on Fullscript.
+Based on a survey conducted internally in 2024 of 64 healthcare providers

Pendulum - Meta ads - GLP-1 Probiotic Pro (July 2025 launch) | Fullscript